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Abstract: 
Background: During the last few years there was wide debate about the interchangeability and 
effectiveness between circulated products containing Glibenclamide in the market.  
Objectives: This study aimed to compare the effectiveness of this product “non-micronized” to the 
originator’s product of Glibenclamide tablets “of micronized” sulfonylurea.  
Methods: 12 volunteers received a dose of 5mg of Glibenclamide (from test and standard products) 
under fasting conditions in two separate sessions using randomized crossover design. Blood glucose 
level for the volunteers was monitored to avoid the development of hypoglycemia. Plasma samples 
were collected over 24 hours and analyzed using HPLC.   
Results: The maximum concentration Cmax for the test and reference products were 2.508 ± 0.104 
and 3.526 ± 0.118 (µg/ml) respectively and the area under the curve AUC0-∞ were 3.511 ± 0.153 
4.572 ± 0.202 (µg.h/ml) for these products respectively, with a difference of about 24% between the 
test and reference products in its AUC.  
Conclusions: The results indicate that the test product is not bioequivalent to reference product. 
The difference in formulation between micronized product and non-micronized product of 
Glibenclamide tablets has impact on clinical outcomes. 
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he chemical content of pharmaceutical 
products was no longer the most 
important indicator for the quality 
measure or quality judgment about generic 
drugs. Some evidences showed the 
importance of other important indicators (e.g. 
bioequivalence, relative potency, etc) which 
should be considered while evaluating the 
quality of pharmaceutical products(1). The 
combined interpretation of quality control 
results with clinical data or therapeutic 
outcomes for any drug could be of potential 
importance. The dosage form should also 
have the capability of delivering this amount 
into the systemic circulation of the patient to 
ensure the achievement of desired effects (2).  
Glibenclamide is a sulfonylurea derivative 
(also known as Glyburide) that is very widely 
used in the treatment of type II diabetes 
_______________________________________________________________________________________________________________ 
1,2. Department of Pharmaceutical Chemistry, Faculty 
of Pharmacy, University of Khartoum 
3. Department of Chemistry, Faculty of Sciences, 
University of Khartoum 
4.  Department of Pharmacology, Faculty of Pharmacy, 
Omdurman Islamic University 
mellitus. The availability of large number of 
authorized products in different markets, lack 
of information about these products’ 
bioavailability data and lack of patients’ 
information and education programs; 
highlights many problems regarding the 
interchangeability of available products in the 
markets and its effectiveness (3). 
Recent discussion was raised among scientists 
in Sudan about quality evaluation of 
authorized products of Glibenclamide tablets. 
The debate was mainly focused on the 
comparative bioavailability characteristics of 
certain product compared to other 
formulations (bioequivalence). It was noticed 
that among patients with diabetes, and mainly 
for economic reasons, the patients tends to 
use one of the products that is non-micronized 
formulation as it is much cheaper in price. 
However, patients complain about the 
effectiveness of this product.  
Objectives: 
to investigate factors affecting the quality of 
clinical outcomes of Glibenclamide in
T
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Khartoum using different investigation 
methods and to evaluate bioequivalence of a 
single dose of test formulation (containing 
Glibenclamide 5 mg tablet, manufactured by 
company C06 - Sudan) and to compare it with 
a single dose of reference formulation 
(containing Glibenclamide 5 mg tablet, 
manufactured by company C09 - Germany) 
under fasting conditions. 
Patients and methods: 
Study design: Comparative in-vivo 
bioavailability (bioequivalence) study, in 
which Glibenclamide concentration in plasma 
was measured for bioavailability and 
bioequivalence.  
Methods: Single dose study was applied with 
a two-period, two-sequence crossover design 
(as recommended for this kind of studies). 
This was applied as two phases of treatment 
separated by 14 days as washing period. 
The volunteers received a dose of 5 mg of 
Glibenclamide (of test and reference 
products) under fasting conditions in two 
separate sessions using a randomized 
crossover design. Plasma samples were 
obtained at selected times over 24 hours and 
stored frozen until analyzed using basic 
HPLC technique. Pharmacokinetic parameters 
were compared using the analysis of variance 
for a cross-over design and ratios of AUC24h 
and Cmax, 90% confidence intervals were 
obtained for summery of the results. Results 
were considered positively if the confidence 
intervals did not exceed the limits of 
acceptance (80--120%) for AUC24h and 
Cmax. 
Subjects: Healthy 12 Sudanese volunteers 
were recruited in this study. The detailed 
process of selecting these subjects followed 
the recommendations of Helsinki Declaration 
regarding the ethical principles for medical 
research involving human subjects(8). All 
subjects were residents of Khartoum State; 
females enrolled were neither pregnant nor 
lactating. The range of age was (≤18 to 55 ≥
years). Health status of the subjects was 
evaluated based on information obtained from 
each volunteer regarding the following: free 
from history of diabetes mellitus (DM), no 
smoking history, no history of hospitalization 
within the last 12 months , no evidence of 
burns, no evidences for impaired renal or 
hepatic functions. ECG, clinical blood 
chemistry, blood pressure were obtained. As 
part of inclusion criteria, all of the volunteers 
were checked to ensure that they didn’t take 
(during the study period or within 1 month 
before) any of the following medicines: 
Allopurinol, Captopril, Enalapril, 
Anticoagulants, coumarin or indandione 
derivative, Miconazole, Fluconazole, Appetite 
suppressants, Corticosteroids thiazide 
Diuretics, Barbiturates, Beta-adrenergic 
blocking agents, Cimetidine, Ranitidine, 
Fluoroquinolones, Quinine, Rifampin, 
Chloramphenicol, NSAIDs, Sulfonamides or 
Hyperglycemia-causing agents. 
Selection of the volunteers: 
The selection process of the volunteers was 
aimed to minimize the variations between the 
individuals participated in this study. Age, 
weight, gender and health status of the 
participants all were taken into 
considerations. The recruitment of the 
subjects in this study was on voluntary basis 
and all of the ethical considerations were 
taken into account. Volunteers received a 
welcoming package to orient them about the 
study (its objectives, methods, instructions for 
preparations, sample collection and other 
relevant information). Besides that, they 
received basic information sheet about them 
to fill. 
Set up: The study was taken place in Soba 
University Hospital after getting the 
permission from the hospital administration.  
Other variability aspects: 
The factors that were expected to affect the 
study were controlled carefully during the 
study course. They include environment, diet, 
fluids intake, physical conditions and timing 
of blood sampling (day or night). 
Standardized information sheet was 
developed and distributed to all of the 
participants prior to the starting date. This 
aimed to ensure the consistency of all 
affecting factors to minimize the variations 
between    subjects    included     and       
hence the results obtained.
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Ethical considerations: This study 
wasconducted by independent professionals 
from the academic sector and was designed 
for scientific and academic purposes only. 
The investigators express no conflict of 
interest in selecting the products or suppliers 
under testing. The principal investigator was 
committed prior to start the study for his 
responsibility to ensure the protection of the 
rights, safety and well-being of subjects 
involved in this study. The ethical approval 
has been obtained from the National Board 
for Ethical Review of Health Research in 
Sudan Ministry of Health. In addition to that, 
the study team included certified medical 
doctor in order to monitor the subjects closely 
during their admission in the hospital. All 
study subjects, after receiving the information 
sheet and upon agreement to taken part of the 
study, were asked to sign a consent form 
before considering him/her as study subject. 
This was kept well with other confidential 
documents under this study. 
Blood sampling scheme: 
The purpose of sampling scheme includes 
mainly the half-life that play critical role in 
determining the elimination profile of 
Glibenclamide. Accordingly its dose response 
curve in addition to the elapsed time to reach 
the maximum concentration (absorption and 
elimination period) were the determinant 
factors for this sampling scheme(10). The 
sampling period and schedule were 
determined to cover 24 hours following drug 
administration. Blood samples (14 samples) 
were collected at 0.25, 0.50, 0.75, 1.0, 1.5, 
2.0, 2.5, 3, 3.5, 4, 4.5, 6, 12 and 24 hours after 
administration of the dose. Using 5 ml 
syringes, the samples were transferred to 
heparinised tubes after labeling. Each sample 
was then centrifuged for five minutes using 
regular centrifuge at 3000 rpm. Serum was 
separated and transferred into 3ml plain 
containers. The samples were re-labeled using 
the final codes, transported and frozen up to 
the time of analysis. Parallel with the 
collection of blood sample, sample collectors 
used small amount of blood (0.1 ml) to 
measure the glucose level in the sample using 
Accu-chek® Glucometer.  
Samples preparation and analysis: 
Basic HPLC techniques were used to measure 
targeted parameters. Analysis was done in 
collaboration with the Central Laboratory in 
Faculty of Science – University of Khartoum.  
Chromatographic conditions: 
The method of analysis adopted for this 
process was developed by SD Rajendran and 
others with some minor modifications as 
needed(10). The HPLC system consisted of a 
Shimadzu LC-10AT liquid chromatographic 
pump, SIL-10a manual injector and SPD-10A 
UV/Vis UV absorbance detector (Shimadzu, 
Kyoto, Japan). Data collection, integration 
and calibration were accomplished using 
Class VP Chromatography Data System 
Version 6.14 computer software (Shimadzu, 
Kyoto, Japan). The chromatographic 
separations of Glibenclamide and internal 
standard (glimepride) were accomplished 
using a 150 mm×4.6 mm ID Shim-Pack VP-
ODS analytical column (SHIMADZU). A 
Guard-Pak precolumn module (Phenomenex, 
USA) containing an ODS cartridge insert was 
placed serially just before the analytical 
column. The mobile phase consisted of 
acetonitrile: 25 mM phosphate buffer (pH: 
3.5) in a combination of 80:20 v/v. Before use 
the mobile phase was degassed by passing it 
through a 0.22µm filter. The mobile phase 
was pumped at an isocratic flow rate of 1 
ml/min at room temperature. The UV 
detection wave length was set at 253 nm. The 
wave-length of 236 nm represented the UV 
maximum of Glibenclamide in acetonitrile: 
water in 1:1 ratio.  
Assay procedure: 
In which a stock solution representing 
100µg/ml of Glibenclamide was prepared in 
acetonitrile: water in 1:1 ratio. These 
solutions were stored at -20o until use. The 
working standard solutions were prepared 
prior to use from the stock solution by 
sequential dilution with a combination of 
acetonitrile: water in 90:10 ratio to yield final 
concentrations of 50, 100, 200, 400, and 500 
ng/ml of Glibenclamide. The internal standard 
stock solution was prepared by dissolving 
1mg of glimepride in 100ml of acetonitrile: 
water in 1:1 ratio. This solution was stored at
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-20o until use. In a 2ml microcentrifuge tube, 
500µl of serum was added along with 500µl 
of internal standard solution. The serum was 
precipitated by the addition of 500µl of 
methanol, and then the tubes were vortexed 
for 30 sec and centrifuged at 5000 g for 8min. 
The supernatant was transferred to a clean, 
similarly labeled tube and was subsequently 
re-centrifuged for 2min. The resulted solution 
was injected in to the HPLC.  
Assay parameters: 
The extraction efficiency of the samples was 
determined by comparing the peak area of 
known amounts Glibenclamide (unextracted) 
in mobile phase that was directly injected to 
peak area of samples containing the same 
amounts of Glibenclamide in plasma after 
extraction. Quantification was based on 
calibration curves constructed using peak area 
ratios of drug to internal standard versus the 
nominal concentration. The procedure was 
repeated on three separate days to allow the 
determination of inter-day precision and 
accuracy. Intra-day accuracy was estimated 
based on the mean percentage error, and the 
inter-day accuracy was calculated as the mean 
of the intra-day accuracy determinations. The 
precision, which was expressed as percentage, 
was evaluated by calculating the intra- and 
inter-day relative standard deviations. The 
standard drug solutions in varying 
concentrations ranging from 50ng/ml to 
500ng/ml were examined by the assay 
procedure. The peak area was calculated. The 
calibration acurvewas plotted using peak area 
vs. oncentration of the standard solutions. 
Data management and analysis: 
General analysis was done manually and by 
using computer programs e.g. SPSS and MS 
Excel. 
Pharmacokinetic analyses: 
The following parameters will be presented 
and discussed below: (1) maximum plasma 
concentration (Cmax) as indicator for 
absorption rate; (2) time to reach the 
maximum plasma concentration (Tmax) as 
indictor for the elimination rate; (3) area 
under of curve (AUC) as it described the total 
amount of drugs available in plasma after the 
administration of the dose; and (4) 
elimination half life time (T½) as indicator for 
the elimination. 
Area Under the Curve (AUC): 
The area under the curve (AUC0-t) was 
calculated using the following formula: 
AUC0-t = � ��� � ����� ���� − �� − 1�
�
���  
Pharmacokinetic parameters were calculated 
as indicted before. Based on these parameters 
the elimination rate constant (KE) was 
obtained using the following formula: 
(KE) = 0.693 / T½ 
The area under the curve to the last 
measurable concentration (AUC0-t) was 
estimated by the linear trapezoidal rule. The 
area under the curve extrapolated to infinity 
(AUC0-∞) was calculated by equation below: 
(AUC0-∞) = AUC0-t + Ct / kE 
* Where Ct is the last measured concentration 
Paired samples analysis was used to compare 
the results of Tmax of the test and the 
reference products. The results were 
considered statistically significant for a P 
value of less than 0.05. The 90% confidence 
intervals of parameters under testing were 
also estimated. The inter-subject variation of 
AUC0-t, AUC0-∞, and Cmax parameters was 
also obtained by calculating the coefficient of 
variation (CV).  
Results: 
The volunteers: 
 Twelve healthy volunteers; 6 men and 6 
women, aged between 20 years and 36 years, 
and with a range of weight between 65 kg and 
94 kg; were enrolled to participate in this 
study. 
Based on the results obtained: 
(KE) Average slope for test product 0.104
(KE) Average slope for reference 
product 0.194
Accordingly the elimination half life (T1/2) in 
hours for each product: 
T½  of test product 6.663
T½of reference product 3.572
The results indicated that the mean “C max”
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of the test product was 2.508 compared to 
2.526 the reference product. On other hand 
the “AUC0 - ∞” of test product was 3.511 
compared to 4.572 the reference product.
 
Table 1: Main pharmacokinetic parameters for test and reference products 
Parameters Test product 
Mean ± SD 
Reference product 
Mean ± SD 
Intra- subject 
CV% 
C max - (µg/ml) 2.508 ± 0.104 3.526 ± 0.118 2.8% 
T max - (hrs) 1.639 ± 1.024 2.167 ± 1.275 63.9% 
AUC0-12 - (µg.h/ml) 0.490 ± 0.188 0.638 ± 0.252 55.7% 
AUC0 - ∞ - (µg.h/ml) 3.511 ± 0.153 4.572 ± 0.202 2.4% 
The table below show the time interval for 
each of the test and reference products to 
reach the maximum concentration, the 
numbers showed the frequency of the 
volunteers. 
Time interval (h) Test Reference 
0,0 – 0,99 3 2 
1,0 – 1,99 1 1 
2,0 – 2,99 2 4 
3,0 – 3,99 3 3 
4.0 – 4.99 3 2 
The AUC0-6, AUC0-∞, Cmax, and Tmax, for 
each pair of products (test vs. reference) in 
this study were statistically different 
(P<0.05), suggesting that the serum profiles 
generated by reference tablets were relatively 
higher than those produced by the test product 
(Table 10). 
Moreover, 90% confidence intervals of the 
AUC0-6, AUC0-∞, and Cmax of the two 
formulations in the study were not found to be 
within the relative bioavailability acceptable 
range of 80-125% (Table 1). Wilcoxon signed 
rank test showed distinct difference between 
the untransformed values of Tmax of the test 
compared to the reference products. The intra-
subject CV for AUC0-6, AUC0-∞, and Cmax 
appeared to be varied and relatively large for 
some AUC0-6 and Tmax. With a difference 
of about 24% between the test product and the 
reference product, the results indicate that the 
test product is not bioequivalent to reference 
product. The results indicated that, the 
probability that the true ratios with respect to 
Cmax and AUC are not acceptable in bio-
equivalence range (which is 80% - 120%). It 
is therefore clear that test product cannot be 
considered bio-equivalent to the reference 
product with respect to the extent of 
absorption as measured by AUC. The fact that 
the two products also differed with respect to 
Cmax which is probably due to differences in 
the extent of absorption rather than the 
difference in the rate of absorption. No 
hazardous side-effects or adverse reactions 
were noticed during the observation of the 
volunteers; however, several of them 
experienced unpleasant symptoms relevant to 
hypoglycemia. This was noticed in 2 
volunteers after the test product and in 3 
volunteers after the reference product. The 
figure below showed the serum glucose level 
versus time for test and reference products. 
 
Figure 1: Serum glucose level for test and 
reference products 
Discussion: 
The  importance of our study are derived from 
thefrom medicines quality monitoring survey 
done in 2008 in Sudan pointed the fact that
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one of the authorized Glibenclamide products 
was among the top three products that the 
doctors complained about its therapeutic 
outcomes4.
WHO guidance on bioavailability and 
bioequivalence stated the following “Two 
medicinal products are bioequivalent if they 
are pharmaceutically equivalent or 
pharmaceutical alternatives AND if their 
bioavailability after administration in the 
same molar dose are similar to such degree 
that their effects, with respect to both efficacy 
and safety, will be essentially the same”5.Our 
study design benefited from the experience 
and guidance of other bodies such as 
FDA6.Most of the published studies in this 
area adopt sample size between 12 – 26 
subjects (depends on the variability of drug 
under study) and this number showed 
sufficient and statistically significant 
evidence7.
The chemical contents of each medicine 
usually play important role in medicines 
ineffectiveness problems. Because it indicates 
that the desired quantity of the medicine is 
available or not as patient need it; and any 
interruption in this relationship could lead to 
failure of therapeutic process12.
As indicated before, based 2008 quality 
monitoring survey and according to the 
results obtained from both data collection 
process and laboratory analysis, it was clear 
there are other reasons contributed to 
ineffectiveness problems associated with 
specific Glibenclamide product in the market. 
Currently there are 16 different formulations 
authorized and available in Sudan and from 
different sources3. On the other hand very 
limited information about their 
bioequivalence or interchangeability was 
known. Due to lack of information about the 
interchangeability of these products and lack 
of programs to inform and educate the 
patients, all of these highlighted the concerns 
about the effectiveness of these products in 
managing the disease in more than (50,000) 
estimated cases of diabetes mellitus (type II) 
in Sudan13.
As stated by Meredith PA14: “For economic 
reasons, the use of generic substitution is 
increasingly being supported by health 
authorities, ......., many developing countries 
do not have the resources or expertise to 
carry out appropriate quality control 
resulting in widespread distribution of 
substandard drugs, ........, a number of 
reports, largely anecdotal, of treatment 
failure or increased adverse events after 
switching brands have cast some doubts upon 
whether bioequivalence testing is sufficient in 
all cases. On the other hand, Tschabitscher D 
and his colleagues urged15: “Since the 
introduction of generic drugs to the 
pharmaceutical market a sometimes 
emotional debate exists whether they are 
well-investigated and of high quality. There is 
some uncertainty about [whether evidence of 
bioequivalence is enough to guarantee 
efficacy and safety of generic drugs]......., the 
importance of bioequivalence studies is 
increasing also due to the large growth of the 
production and consumption of generic 
products....., the registration of generic 
products does not demand complicated and 
expensive clinical study contrary to original 
product. The comparison of the original and 
the generic product via bioequivalence study 
is suggested as sufficient”. 
After reviewing the results of each product 
under testing it was noticed that the main 
difference between the two products, beside 
other minor differences, was its formulation 
characteristics. The local product was a non-
micronized formulation unlike the reference 
product which was formulated using a 
micronized powder. This was significant 
finding and has major impact on the 
registration requirements of this drug (and 
other similar drugs) in the country. According 
to the results obtained from the survey, from 
chemical laboratory analysis and form this 
study; it becomes clear that the risks 
associated with poor formulation of 
Glibenclamide products is the major cause 
behind the complaints reported about this 
drug. These observations and feedback about 
the specific locally manufactured product 
support the complaints received about the 
problem. This was supported by the study 
taken by Coppack and other co-workers in
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which the results showed the clear differences 
in pharmacokinetic characteristics of the 
different types of Glibenclamide 
formulation16. This also supports the 
hypothesis behind the insufficiency of 
chemical analysis alone to verify the quality 
as it was shown in this bioequivalence study. 
Although, measuring the quality of 
pharmaceutical products was changed 
markedly in the last decade, nevertheless, 
chemical content of pharmaceutical products 
alone is not the only suitable indicator to 
measure the quality of some generics. As 
evidences showed, other important indicators 
that should be considered when we evaluate 
the quality of these drugs. The combined 
interpretation of quality control and quality 
assurance results with other data from clinical 
trials and feedback about therapeutic 
outcomes becomes highly important. This is 
particularly significant in order to include or 
exclude any potential risk factors that 
contribute to treatment failure or poor clinical 
outcomes.  
Conclusions: 
This study provided necessary information 
about the assessment of medicines quality in 
order to inform the decision makers about 
reviewing the registration decisions of 
Glibenclamide products that are available in 
the market. The study highlighted the impact 
of poor drug formulation on quality and 
effectiveness especially for medicines that are 
chronically used. 
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